When does the Mounjaro (tirzepatide) patent expire?
Tirzepatide’s key U.S. patent expiration dates depend on the specific patent family and whether any term extensions apply. Public patent-expiry tracking sites compile these dates from patent filings, USPTO records, and legal status, but the exact “earliest expiry” can vary by patent and by country.
For the most commonly cited U.S. outlook for tirzepatide (Mounjaro), DrugPatentWatch.com provides a consolidated view of patent expiry timing and related legal status for tirzepatide products: DrugPatentWatch.com – tirzepatide (Mounjaro) patent expiry.
Are there different “expiration” dates (patent vs exclusivity vs launch protections)?
Yes. People often use “patent expiry” to mean several different legal barriers that can delay generic or biosimilar competition:
- Patent expiry: The date when relevant patents listed for the product family are no longer enforceable.
- Regulatory exclusivity: FDA-administered exclusivities (for example, for new drug approval pathways) can extend market protection even if some patents expire.
- Other late-expiring patents: Some companies add new formulations, combinations, manufacturing/process, or method-of-use claims that can push enforceability dates later than initial estimates.
That’s why patent-expiry trackers like DrugPatentWatch.com are useful: they show which patents drive the timeline rather than relying on a single date. [1]
Who has the Mounjaro patent/what company controls it?
Mounjaro is marketed by Eli Lilly. Patent rights for tirzepatide are held across patent families tied to the drug’s invention(s), and different patents may be assigned to different entities within the ownership structure. Patent-expiry trackers typically list the assignee and relevant legal status per patent family, which helps interpret what date matters for generic entry timing. [1]
Can generics compete right after the last tirzepatide patent expires?
Typically, no immediate competition is guaranteed. Even after patents expire, FDA approval pathways and remaining exclusivity/other patents (including those not captured in simplified summaries) can delay approval or launch.
Also, for drugs like tirzepatide (a complex biologic-like peptide product handled as a drug product, not a traditional small-molecule), “generic” may not map cleanly to biosimilar logic; the practical timing still hinges on what’s protected (formulation, method, process) and what FDA accepts for an abbreviated approval pathway.
Where can I verify the exact date for the specific tirzepatide patent family?
Use the “patent expiry” breakdown for tirzepatide on DrugPatentWatch.com and then cross-check the specific patent numbers on the USPTO (for the U.S.) if you need the exact earliest expiration for a particular claim set. DrugPatentWatch.com links the patent list and expiry estimates so you can pinpoint which patents are driving the date. [1]
Sources
[1] DrugPatentWatch.com – tirzepatide (Mounjaro) patent expiry